Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
InChi: InChI=1S/C6H12F2N2O2
Derazantinib is effective at inhibiting tumor growth in FGFR2 altered
C4H6O4/c1-31-9-11-33(12-10-31)18-4-7-32(8-5-18)19-15-29-26-22(16-30-34(26)17-19)20-3-6-28-24-14-23(27)25(35-2)13-21(20)24
Temsirolimus treatment for 2 weeks also delays the growth of rapamycin-resistant U251 xenografts by 148%
or 400 mg/kg/day COH29 results in a dose-dependent inhibition of tumor xenograft growth
(S,R,S)-AHPC-C2-PEG4-N3 potassium InChi: InChI=1S/C6H12F2N2O2(S, R, S) AHPC C2 PEG4 N3 (VH032 C2 PEG4 N3) is a synthesized E3 ligase ligand linker conjugate that incorporates the (S, R, S) AHPC based VHL ligand and 4 unit PEG linker used in PROTAC technology. (S, R, S) AHPC C2 PEG4 N3 can be used in the synthesis of vRucaparib TP4 (HY 130647). vRucaparib TP4 a highly potent PARP1 degrader with a half maximal degrading concentration (DC50) of 82 nM. Product information Molecular Weight: 703. 85 Formula:
US$ 580.00
US$ 60.95
US$ 114.50
US$ 33.00
US$ 48.00
US$ 44.00
US$ 646.00
US$ 185.00
US$ 795.00
US$ 795.00
US$ 65.00
US$ 22.95
US$ 629.50